Vivere Oncotherapies’ mission is to revolutionize gene therapy delivery to unlock the full potential of immunotherapy for cold, solid tumors.
Vivere Oncotherapies is developing best-in-class, IV-administered oncotherapy products with improved delivery, efficacy, and safety for the treatment of solid cancers using our proprietary discovery platform. Our experienced leadership team is applying our powerful protein engineering platform to generate improved delivery vehicles that can selectively replicate within tumors, mediate multi-tumor antigen targeting by immune cells, and express multiple cargoes that overcome the immunosuppressive environment of cold tumors. We are on a bold mission to provide solutions to patients with immunologically cold, solid tumors for which there are not effective standards of care.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 2625 Durant Ave, Berkeley,california 94704,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Berkeley, California
Vivere Oncotherapies Questions
Vivere Oncotherapies's LinkedIn profile is https://www.linkedin.com/company/vivere-oncotherapies
Vivere Oncotherapies has
7 employees.
View email and phone details for 7
employees at Vivere Oncotherapies.
Vivere Oncotherapies's industry is
Biotechnology Research
Vivere Oncotherapies's top competitors are
Iris Medicine,
Arcadia Science,
Qb3,
4d Molecular Therapeutics,
Bakar Bio Labs,
Abbvie,
Hexembio,
Catenabio,
Inapill,
Acurex Biosciences.
Vivere Oncotherapies's categories are Biotechnology Research
Vivere Oncotherapies's founding year is 2022
